Answers are grounded in this paper and cite their sources.
Review explores quality of life benefits of cemiplimab over chemotherapy in lung cancer, indicating positive outcomes.
Collectively, the current data support the GHS/QoL benefit of first-line cemiplimab monotherapy versus chemotherapy overall and in multiple subpopulations of patients with programmed cell death-ligand 1 expression ≥50% advanced non-small cell lung cancer.
No takes yet. Share an insight, caveat, or question.
Gandara et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: